PillRx only · Injection, Solution · Intra-Arterial
Methotrexate
Methotrexate Sodium
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US3 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$1.218
Latest avg · Jul 22, 2026
+72%
Since Nov 19, 2025
1
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
975
Rx · 2026 Q1
5.7K
Units dispensed
-42%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Teva Parenteral Medicines, Inc. | unknown | 3 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Mar 13, 2023SHORTAGEDrug shortage: Methotrexate Sodium Injection (Teva Pharmaceuticals USA, Inc.)
Methotrexate Sodium Injection — reported in shortage by Teva Pharmaceuticals USA, Inc.. Therapeutic category: Oncology, Rheumatology.